A meta-analysis of Osimertinib for advanced NSCLC with EGFR mutations revealed that the most common adverse events were diarrhea and rash, with combined incidences of 44% and 42%, respectively, followed by dry skin (29%). This evidence concerns the gene EGFR and non-small cell lung carcinoma.